OSI Pharmaceuticals Announces Conference Call on ODAC Review of Tarceva® for Use as First-line Maintenance Therapy in Advanc...
December 16 2009 - 4:50PM
Business Wire
OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that the
Company will host a live conference call Thursday, December 17, at
8:30 AM Eastern Time to discuss the Oncologic Drug Advisory
Committee (ODAC) panel’s review of the supplemental New Drug
Application (sNDA) for use of Tarceva® (erlotinib) as first-line
maintenance therapy for patients with advanced or metastatic
non-small cell lung cancer whose cancer has not progressed
following first-line treatment with platinum-based
chemotherapy.
To access the live call or the seven-day archive via the
Internet, log on to www.osip.com. Please connect to the Company’s
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be needed to
access the webcast. Alternatively, please call 1-877-879-6174
(U.S.) or 1-719-325-4758 (international) to listen to the call. The
conference ID number for the live call is 7991541. Telephone replay
is available approximately two hours after the call through
December 31, 2009. To access the replay, please call 1-888-203-1112
(U.S.) or 1-719-457-0820 (international) and reference ID number
7991541.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality, novel and differentiated targeted medicines designed
to extend life and improve the quality of life for patients with
cancer and diabetes/obesity. For additional information about OSI,
please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, OSI's and its collaborators'
abilities to effectively market and sell Tarceva and to expand the
approved indications for Tarceva, OSI’s ability to protect its
intellectual property rights, safety concerns regarding Tarceva,
competition to Tarceva and OSI’s drug candidates from other
biotechnology and pharmaceutical companies, the completion of
clinical trials, the effects of FDA and other governmental
regulation, including pricing controls, OSI's ability to
successfully develop and commercialize drug candidates, and other
factors described in OSI Pharmaceuticals' filings with the
Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024